Must read on a very undervalued low float biotech LJPC..
La Jolla Pharmaceutical Company (LJPC) is developing treatments that significantly improve outcomes in patients with life-threatening diseases. Their current efforts focus on the clinical evaluation of GCS-100, a galectin antagonist, as a treatment for chronic organ disease and LJPC-501 an antagonist of the renin-angiotensin pathway, as a treatment for hepatorenal syndrome, a life-threatening form of progressive renal failure in patients with liver cirrhosis or fulminant liver failure.
The shares have fallen from ~$18 a share to just over $10 a share over the past month. This decline has triggered some insider buying. An insider bought some 8,000 shares in two transactions over the past ten days. Another insider bought 3,000 shares in February. There has been no insider selling over the past year.
Only three analysts cover the stock currently probably due to its small market capitalization (~$75mm). These analysts have price targets of $33, $34 and $54 a share respectfully on the shares. This is another biotech play that analysts believe could triple or more based on their price targets. The company recently posted results from a Phase II trial of GCS-100 in chronic kidney disease.
Editor's Note: This article covers a stock trading at less than $1 per share and/or with less than a $100 million